Welcome to our dedicated page for GlycoMimetics news (Ticker: GLYC), a resource for investors and traders seeking the latest updates and insights on GlycoMimetics stock.
GlycoMimetics, Inc. (GLYC) is a clinical-stage biotechnology company dedicated to developing transformative therapies for serious diseases like sickle cell disease, cancer, and other conditions with high unmet medical needs. Founded in 2003, the company leverages its proprietary glycobiology technology to create novel glycomimetic drugs. These drugs are designed to mimic the structure of carbohydrates that play critical roles in various biological processes, potentially offering new avenues of treatment for complex diseases.
GlycoMimetics focuses on areas where carbohydrate biology is crucial, particularly in inflammation, cancer, and infection. The company's robust and diversified product pipeline includes multiple clinical candidates currently in various stages of development. These candidates aim to inhibit disease-related carbohydrate functions, thereby providing hope for patients who currently have limited treatment options.
The company's mission is to advance its research, clinical candidates, and ultimately deliver breakthrough treatments to improve patients' lives. GlycoMimetics is publicly traded on the NASDAQ under the symbol GLYC, reflecting its ongoing commitment to transparency and growth. Recent achievements and current projects highlight the company's commitment to innovation and patient care. GlycoMimetics continues to build strategic partnerships to enhance its research and development efforts, further solidifying its position as a leader in biotechnology.
By using expertise in carbohydrate chemistry and a deep understanding of carbohydrate biology, GlycoMimetics is at the forefront of developing treatments that address significant medical challenges. The company's ongoing projects and collaborations underscore its dedication to making a meaningful impact in the field of biotechnology.
GlycoMimetics, Inc. (Nasdaq: GLYC) reported its financial results for Q4 and the full year ended December 31, 2020. The company had cash and cash equivalents of $137.0 million as of year-end. Revenue for 2020 was $10.2 million, significantly higher than 2019, reflecting progress in collaborations for uproleselan and GMI-1687. The pivotal trial for uproleselan continues to enroll patients, with completion expected in H2 2021. The company shifted focus from rivipansel to GMI-1687, which may better suit outpatient care for sickle cell patients.
GlycoMimetics, Inc. (Nasdaq: GLYC) announces participation in three virtual healthcare conferences in March 2021. Key events include:
- Cowen 41st Annual Health Care Conference: March 1-4, featuring Eric Feldman on a Leukemias Panel on March 3.
- H.C. Wainwright Global Life Sciences Conference: March 9-10, with CEO Rachel King presenting a corporate overview.
- 33rd Annual Virtual Roth Conference: March 15-17, where Rachel King will again present.
GlycoMimetics focuses on novel glycomimetic drugs for hematology-oncology.
GlycoMimetics, Inc. (Nasdaq: GLYC) will host a conference call on March 2, 2021, at 8:30 a.m. ET to report its fourth quarter and year-end 2020 financial results. The call can be accessed domestically at (844) 413-7154 or internationally at (216) 562-0466 with participant code 1034166. A webcast replay will be available for 30 days post-call. The company focuses on developing novel glycomimetic drugs for unmet medical needs in hematology-oncology, including the evaluation of uproleselan in clinical trials.
GlycoMimetics, Inc. (Nasdaq: GLYC) has promoted Eric Feldman, M.D., to Senior Vice President and Chief Medical Officer, effective immediately. Dr. Feldman, previously Vice President, Global Clinical Development, is noted for his expertise in developing therapies for leukemias. He will lead the uproleselan program, currently in Phase 3 trials. Dr. Helen Thackray, former Chief Medical Officer, will leave the company after 15 years. Uproleselan, an investigational treatment for AML, has received Breakthrough Therapy designation from the FDA, showing promising results in clinical trials.
GlycoMimetics (Nasdaq: GLYC) presented new data on rivipansel at the 62nd ASH Annual Meeting, confirming its efficacy in treating acute vaso-occlusive crises (VOC) in sickle cell disease. The analysis from an Open Label Extension trial revealed that early treatment with rivipansel resulted in a median hospital stay of 80.89 hours, compared to 103.97 hours for placebo, a significant difference. The pediatric data showed a reduction of 29.3 hours in the median time to resolution of pain. CEO Rachel King emphasized ongoing FDA interactions for future clinical development.
GlycoMimetics (Nasdaq: GLYC) announced promising results for its investigational drug uproleselan at the 62nd ASH Annual Meeting. The drug significantly reduced tumor burden and improved survival rates in animal models of acute myeloid leukemia (AML) when combined with venetoclax and a hypomethylating agent. CEO Rachel King emphasized the potential for further clinical trials to explore this combination. Uproleselan is currently in Phase 3 development for AML and has received Breakthrough Therapy designation from the FDA.
GlycoMimetics, Inc. (Nasdaq: GLYC) announced that CEO Rachel King will present at the Stifel 2020 Virtual Healthcare Conference on November 17 and the Jefferies Virtual London Healthcare Conference on November 19. The presentations can be accessed on the company's website under the Investors tab. GlycoMimetics is focused on innovative glycomimetic drugs for unmet medical needs, including treatments for acute myeloid leukemia and sickle cell disease. Uproleselan is in a Phase 3 trial for relapsed/refractory AML, and Rivipansel is investigating acute VOC in SCD.
GlycoMimetics, Inc. (Nasdaq: GLYC) reported Q3 2020 financial results, highlighting cash and equivalents of $142.9 million. The Phase 3 trials for uproleselan in AML are progressing, with enrollment completion projected in H2 2021. Significant data from rivipansel's Phase 3 RESET trial indicates improved discharge times in early crisis treatment. General and administrative expenses rose to $4.1 million, while R&D expenses remained stable at $10.7 million for Q3. CEO Rachel King emphasized the company's commitment to advancing its pipeline amidst the ongoing pandemic.
GlycoMimetics, Inc. (Nasdaq: GLYC) announced that five abstracts from its clinical portfolio have been accepted for presentations at the 62nd ASH Annual Meeting, scheduled for December 5-8, 2020. Key highlights include positive findings from the Phase 3 RESET study of rivipansel, indicating shorter hospital stays and reduced opioid use for sickle cell disease patients. Additionally, GMI-1687's potential for intravenous and subcutaneous administration was presented, alongside data on uproleselan's efficacy in acute myeloid leukemia (AML). These presentations suggest novel treatment pathways for unmet medical needs.
GlycoMimetics, Inc. (Nasdaq: GLYC) is set to host a conference call on November 6, 2020, at 8:30 a.m. ET to discuss its third quarter financial results. The call can be accessed domestically at (844) 413-7154 or internationally at (216) 562-0466, with a participant code of 3073766. The company is focused on developing glycomimetic drugs for unmet medical needs, with late-stage programs including uproleselan, currently in a Phase 3 trial for AML, and rivipansel for SCD. A webcast replay of the call will be available for 30 days on their website.
FAQ
What is the current stock price of GlycoMimetics (GLYC)?
What is the market cap of GlycoMimetics (GLYC)?
What does GlycoMimetics, Inc. specialize in?
What are glycomimetic drugs?
What is the company's mission?
When was GlycoMimetics founded?
What is the stock symbol for GlycoMimetics?
What diseases is GlycoMimetics targeting with its treatments?
How does GlycoMimetics develop its treatments?
What recent achievements has GlycoMimetics made?
How can I get the latest news about GlycoMimetics?
What is the significance of GlycoMimetics' research?
